Abstracts tagged "Disease-Modifying Antirheumatic Drugs (Dmards)"

Abstract Number: 2174 • ACR Convergence 2023
JAK Inhibitors in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 73 Patients, 55 of Baricitinib
Ana Serrano-Combarro¹, Belén Atienza-Mateo², Jesus Alejandro Valero-Jaimes³, Marta Pastor-Mena⁴, Rafael Benito Melero-Gonzalez⁵, David Castro-Corredor⁶, Maria Martin-Lopez⁷, Santos Castañeda⁸, Jesus Loarce-Martos⁹, Natalia Mena Vazquez¹⁰, Carmen carrasco-Cubero¹¹, Carolina Diez-Morrondo¹², andrea Garcia-Valle¹³, Gema Bonilla¹⁴, Juan Maria Blanco-Madrigal¹⁵, Natividad del Val del Amo¹⁶, Nuria Vegas Revenga¹⁷, Lorena Perez-Albadalejo¹⁸, Rafaela Ortega Castro¹⁹, Deseada Palma-Sanchez²⁰, Ana Maria fernandez-Ortiz²¹, Patricia Lopez-Viejo²², Maria Lopez-Lasanta²³, Marta Garijo Bufort²⁴, Ivette Casafont-Sole²⁵, Olga Maiz-Alonso²⁶, Juan Moreno-Morales²⁷, Ana Urruticoechea²⁸, Carolina Perez-Garcia²⁹, Jose Rosas³⁰, Virginia Ruiz-Esquide³¹, Delia Fernández-Lozano³², Ignacio Brana Abascal³³, Evelin Cecilia Cervantes-Perez³⁴, Julia Fernandez-Melon³⁵, Cristina Fernandez³⁶, Bryan Josue Flores Robles³⁷, Diego Ferrer³⁸ and Ricardo Blanco³⁹, ¹Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, Spain, ²Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Hospital Bidasoa, Irún, Spain, ⁴Hospital de Jerez de la Frontera, Cádiz, Spain, ⁵CHU Vigo, O Carballino, Spain, ⁶General University Hospital of Ciudad Real, Santa Cruz de Mudela (Ciudad Real), Spain, ⁷Hospital 12 de Octubre, Madrid, Spain, ⁸Hospital Universitario de la Princesa, Madrid, Spain, ⁹Ramón y Cajal University Hospital, Madrid, Spain, ¹⁰IBIMA, Málaga, Spain, ¹¹Department of Rheumatology, Hospital Universitario de Badajoz, Badajoz, Spain, ¹²Division of Rheumatology, Hospital de León, León, Spain, ¹³Division of Rheumatology, Complejo Asistencial Universitario de Palencia, Palencia, Spain, ¹⁴Department of Rheumatology, Hospital Clínico Universitario La Paz, Madrid, Spain, ¹⁵Division of Rheumatology, H. Universitario de Basurto, Bilbao, Spain, ¹⁶Complejo Hospitalario de Navarra, Pamplona, Spain, ¹⁷Hospital Galdakao- Usansolo, Galdakao, Spain, ¹⁸Division of Rheumatology, Hospital Universitario de Jaén, Jaén, Spain, ¹⁹Hospital Reina Sofía, Cordoba, Spain, ²⁰Hospital Rafael Mendez, Lorca, Spain, ²¹CHU Badajoz, Badajoz, Spain, ²²Division of Rheumatology, Hospital Severo Ochoa, Leganéz, Spain, ²³Hospital Universitari Vall d'Hebron, Rheumatology, Barcelona, Spain, ²⁴H. de Sagunto, Valencia, Italy, ²⁵Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²⁶University Hospital Donostia, San Sebastian, Spain, ²⁷Hospital Universitario Santa Lucia Cartagena, Cartagena, Spain, ²⁸Hospital Can Misses, Ibiza, Spain, ²⁹Hospital del Mar, Barcelona, Spain, ³⁰Hospital Marina Baixa, Alicante, Spain, ³¹Hospital Clinic, Rheumatology, Barcelona, Spain, ³²Hospital de Mérida, Merida, Spain, ³³Division of Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Spain, ³⁴Complexo Hospitalario Universitario de Pontevedra, Pontevedra, Spain, ³⁵Division of Rheumatology, Hospital Universitario Son Espases, Palma de Mallorca, Spain, ³⁶Hospital Universitario San Juan de Alicante, Alicante, Spain, ³⁷Hospital Universitario San Pedro, Logroño, Spain, ³⁸Division of Pneumology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³⁹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Abatacept and Rituximab are the recommended drugs. JAK inhibitors (JAKi) have…
Abstract Number: 2544 • ACR Convergence 2023
Microbial Metabolism of Methotrexate Contributes to Its Pharmacokinetics in Vivo
Diego Orellana, Mohana Mukherjee, Moriah Sandy, Peter Turnbaugh and Renuka Nayak, University of California San Francisco, San Francisco, CA
Background/Purpose: Methotrexate (MTX) is a first-line treatment drug used in rheumatoid arthritis (RA) patients. However, only 30-40% of patients tolerate the drug and achieve adequate…
Abstract Number: 110 • 2023 Pediatric Rheumatology Symposium
Medications Affect Antibody Responses to COVID-19 Vaccinations in Children with Autoimmune Diseases
Janna Shapiro¹, Florence Choi², Amy Xu³, Trang Duong⁴, Tania Watts¹, Anne-Claude Gingras⁵, Sasha Bernatsky⁶, Susanne Benseler⁷ and Rae Yeung⁸, ¹Department of Immunology, University of Toronto, Toronto, ON, Canada, ²Division of Rheumatology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ³The Hospital of Sick Children, Department of Paediatrics, University of Toronto, Division of Rheumatology; Cell Biology Program, The Hospital for Sick Children Research Institute, Toronto, ON, Canada, ⁴Cell Biology Program, The Hospital for Sick Children Research Institute, Toronto, ON, Canada, ⁵Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health; Department of Molecular Genetics, University of Toronto, Toronto, ON, ⁶Centre for Outcomes Research and Evaluation (CORE), Research Institute of the McGill University Health Centre, Montreal, Québec, Canada; Division of Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁷Division of Rheumatology, Department of Paediatrics, The Alberta Children’s Hospital, Calgary, AB, ⁸The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: To compare antibody responses to COVID-19 vaccines among children with autoimmune diseases taking different classes of immunosuppressantsMethods: A prospective observational study was conducted at…
Abstract Number: 118 • 2023 Pediatric Rheumatology Symposium
Serum Hepatocyte Growth Factor in Children with Juvenile Idiopathic Arthritis
Natalia Shevchenko and Olga Pavlova, V. N. Karazin Kharkiv National University, Kharkiv, Ukraine
Background/Purpose: Only limited data are available on the risk of liver fibrosis in patients with rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) on long-term…
Abstract Number: L09 • ACR Convergence 2022
Impact on Access to Methotrexate in the Post-Roe Era
Kristin Wipfler¹, Adam Cornish¹, Rebecca Schumacher², Yomei Shaw³, Patricia Katz⁴ and Kaleb Michaud⁵, ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, ³FORWARD, The National Databank for Rheumatic Diseases, Santa Fe, NM, ⁴UCSF, San Rafael, CA, ⁵University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Methotrexate is the first line therapy for RA and is used to treat several other rheumatic and non-rheumatic disorders. In high doses, it can…
Abstract Number: 0093 • ACR Convergence 2022
Comparison of Faculty and Fellow Prescribing Patterns for Rheumatoid Arthritis in an Urban, Academic Hospital
Ana Valle¹, Xianhong Xie², Don-Andre Jackson³ and Irene Blanco⁴, ¹Montefiore Medical Center, New York, NY, ²Department of Epidemiology & Population Health/Albert Einstein College of Medicine, Bronx, NY, ³Griffin Health, Stamford, CT, ⁴Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Timely initiation of DMARDs in rheumatoid arthritis (RA) is necessary to prevent significant morbidity and mortality. Yet, patients from marginalized groups are less likely…
Abstract Number: 0295 • ACR Convergence 2022
Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic DMARDs: Results Through 5 Years from the SELECT-NEXT Study
Gerd Burmester¹, Filip Van den bosch², John Tesser³, Anna K Shmagel⁴, Yuanyuan Duan⁴, Nasser Khan⁵, Heidi Camp⁶ and Alan Kivitz⁷, ¹Charité University Medicine Berlin, Berlin, Germany, ²Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium, ³Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ⁴AbbVie, Inc., North Chicago, IL, ⁵AbbVie, Inc., Abbott Park, IL, ⁶Abbvie, Winnetka, IL, ⁷Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA
Background/Purpose: In the phase 3 SELECT-NEXT study, upadacitinib (UPA) demonstrated efficacy at wk 12 and sustained efficacy up to wk 60 in patients with rheumatoid…
Abstract Number: 0535 • ACR Convergence 2022
Increase Rates of Bacterial Infection in Patients with ‘Pre-RA’
Duncan Porter¹, Sahil Jain² and Fraser Morton³, ¹Gartnavel General Hospital, Bearsden, United Kingdom, ²Gartnavel General Hospital, Glasgow, Scotland, United Kingdom, ³University of Glasgow, Glasgow, Scotland, United Kingdom
Background/Purpose: In 'pre-RA' there is evidence of disordered immunity manifest by the presence of auto-antibodies, increased concentration of pro-inflammatory cytokines (e.g. TNF) and acute phase…
Abstract Number: 0791 • ACR Convergence 2022
Immunogenicity and Safety of a Three-dose SARS-CoV-2 Vaccination Strategy in Patients with Immune-mediated Inflammatory Diseases on Immunosuppressive Therapy
Ingrid Jyssum¹, Anne Therese Tveter¹, Joe Sexton¹, Ingrid Egeland Christensen¹, Siri Mjaaland², David Warren³, Tore K. kvien¹, Kristin Hammersbøen Bjørlykke⁴, Grete Birkeland Kro³, Jørgen Jahnsen⁴, Ludvig A. Munthe³, Espen Haavardsholm¹, Gunnveig Grødeland³, Sella Aarrestad Provan¹, Kristin Kaasen Jørgensen⁴, Guro Goll¹ and Silje Watterdal Syversen¹, ¹Diakonhjemmet Hospital, OSLO, Norway, ²Norwegian Institute of Public Health, Oslo, Norway, ³Oslo University Hospital, Oslo, Norway, ⁴Akershus University Hospital, Oslo, Norway
Background/Purpose: Humoral vaccine responses to SARS-Cov-2 vaccines are impaired and short lasting in patients with immune-mediated inflammatory diseases (IMIDs). Concerns have been raised regarding their…
Abstract Number: 0926 • ACR Convergence 2022
Methotrexate Polyglutamates Exposure – Response Modelling in a Large Cohort of Rheumatoid Arthritis Patients Starting Methotrexate
Renske Hebing¹, Imke Bartelink², Helen Gosselt³, Marry Lin³, Sandra Heil⁴, Robert De Jonge⁵ and Ron Mathot², ¹Amsterdam Rheumatology and immunology Center, Amsterdam UMC – location Reade, Amsterdam, Netherlands, ²Department of Pharmacy and Clinical Pharmacology, Amsterdam University Medical Centers – location AMC, Amsterdam, Netherlands, ³Department of Clinical Chemistry, Amsterdam University Medical Centers – location VUMC, Amsterdam, Netherlands, ⁴Department of Clinical Chemistry, Erasmus MC, Rotterdam, Netherlands, ⁵Department of Clinical Chemistry, Amsterdam University Medical Centers, Amsterdam, Netherlands
Background/Purpose: Optimal dosing of low-dose methotrexate (MTX) is a challenge in rheumatoid arthritis (RA) because of substantial interpatient variation of response and because no stable…
Abstract Number: 1209 • ACR Convergence 2022
Impact of Change in Disease Modifying Antirheumatic Drug Therapy on Disease Activity Measures: Findings from a Large Contemporaneous Real-World Longitudinal Database of Psoriatic Arthritis Patients
Zhaohui Su¹, Lauren Stevens², Tom Brecht¹, Jessica Paulus¹ and Stefan Weiss³, ¹OM1, Inc., Boston, MA, ²OM1, Inc., Lexington, KY, ³OM1, Inc., Chapel Hill, NC
Background/Purpose: While many clinical trials provide direct comparisons between biologic disease modifying antirheumatic drugs (bDMARD) and nonbiologic DMARDs (nDMARD), there is a need for to…
Abstract Number: 1585 • ACR Convergence 2022
Decreased Discontinuation and Switching of B/tsDMARD Therapy in RA Patients When Treatment Is Aligned with a Molecular Signature Response Classifier: An Analysis from the Study to Accelerate Information of Molecular Signatures (AIMS)
Jeffrey Curtis¹, Emelly Rusli², Lixia Zhang², Christina Le-Short², Alix Arnaud², Johanna Withers³ and Sam Asgarian², ¹University of Alabama at Birmingham, Hoover, AL, ²Scipher Medicine Corporation, Waltham, MA, ³Scipher Medicine Corportaion, Waltham, MA
Background/Purpose: Rheumatoid arthritis (RA) patients with inadequate response to methotrexate often experience trial-and-error treatment selection due to a lack of guidance from clinical guidelines or…
Abstract Number: 1958 • ACR Convergence 2022
The Increased Risk of Staphylococcus Aureus Bacteremia in Rheumatoid Arthritis – What Is the Impact of Glucocorticoids, Biologic Disease-Modifying Anti-Rheumatic Drugs and Disease Activity: A Danish Nationwide Nested Case-Control Study in the DANBIO Registry
Sabine Dieperink¹, Bente Glintborg², Frank Mehnert³, Mette Nørgaard³, Louise Bruun Oestergaard⁴, Thomas Benfield⁵, Christian Torp-Pedersen⁶, Andreas Petersen⁷ and Merete Lund Hetland¹, ¹Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark, ²Rigshospitalet, Glostrup, Virum, Denmark, ³Aarhus University Hospital, Aarhus, Denmark, ⁴Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark, ⁵Copenhagen University Hospital - Amager and Hvidovre, Copenhagen, Denmark, ⁶Copenhagen University Hospital - North Zealand, Copenhagen, Denmark, ⁷Statens Serum Institut, Copenhagen, Denmark
Background/Purpose: Staphylococcus aureus bacteremia (SAB) has high mortality.[1] We have previously identified an approximately doubled risk in patients with rheumatoid arthritis (RA),[2] but the role…
Abstract Number: 2146 • ACR Convergence 2022
Efficacy of Upadacitinib in Patients with Psoriatic Arthritis and Prior Exposure to Anti-TNF Therapy in the SELECT-PsA 2 Trial Through 2 Years
Philip J Mease¹, Rodrigo Luppino Assad², Shigeyoshi Tsuji³, Pascal Richette⁴, Arathi Setty⁵, Erin McDearmon-Blondell⁶, Tianming Gao⁵, Sandra Ciecinski⁶ and Filip Van den bosch⁷, ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ²Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil, ³Department of Orthopaedics and Rheumatology, Nippon Life Hospital, Osaka, Japan, ⁴Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France, ⁵AbbVie, Inc., North Chicago, IL, ⁶AbbVie, Inc., Mettawa, IL, ⁷Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium
Background/Purpose: Patients with psoriatic arthritis (PsA) who experience anti-TNF failure and switch to another TNF inhibitor as second- or third-line therapy typically show poorer responses…
Abstract Number: 0105 • ACR Convergence 2022
Supplemental Primary Dose of the COVID-19 Vaccine in Immunosuppressed Patients on DMARDs and Biologic Agents
Archanaa Murugan¹, Ximena Ruiz² and Leslie Harris Jr.¹, ¹University of Alabama at Birmingham- Internal Medicine- Montgomery, Montgomery, AL, ²University of Alabama at Birmingham- Division of Clinical Immunology and Rheumatology, Montgomery, AL
Background/Purpose: Immunosuppressive states can attenuate the immunogenicity of the COVID-19 vaccines. Some studies have shown an improved immune response with a supplemental primary dose. In…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].